



August 01, 2025

To,
Listing/ Compliance Department

BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
SCRIP CODE: 543748

Dear Sir/Madam,

To,
Listing/ Compliance Department

**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Sub: Intimation of Board Meeting
**Ref: Regulation 29 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015**

Pursuant to the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors of Aarti Pharmalabs Limited is scheduled to be held on August 12, 2025, inter alia, to consider and approve the Unaudited Financial Results (standalone and consolidated) for the quarter ended June 30, 2025 along with the Limited Review Reports of the Auditors for the corresponding period.

In view of the above and pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in terms of Code for Prevention of Insider Trading in the Securities of the Company, the Trading Window for transactions in the securities of the Company which was closed from July 01, 2025, shall remain closed until August 14, 2025 for the purpose of announcement of aforesaid results.

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND HEAD LEGAL
ACS: 22565

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@artipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655